In our series of bIMDs, all patients were on prior mould‐active AFP for median of 102 days, suggesting that host factors such as primary graft failure and relapsed disease with secondary neutropenia potentially contributed to acquisition of IMD, as shown in our analysis. This evidence concerns the gene AFP and neutropenia.